first trust dsip (Delta Sleep-Inducing Peptide) 🧠💤 What is DSIP and

Protocol 1: moderate weight loss (10-15% body weight) Goal: Steady, sustainable weight loss with minimal side effects Tirzepatide approach: Standard escalation to 5-7.5 mg Hold at the dose where you achieve consistent weekly loss of 0.5-1% body weight Expected timeline: 24-36 weeks to target Likely maintenance dose: 5-7.5 mg Retatrutide approach: Standard escalation to 4 mg 4 mg delivered 12.9% weight loss at 24 weeks in trials Hold at 4 mg if achieving target rate Expected timeline: 20-30 weeks to target For moderate goals, both compounds work well at their lower dose ranges

Watch-outs to know: Anecdotally, people who take ipamorelin report side effects like mild swelling and headaches, facial redness, injection-site reactions, tingling or numbness, and water retention

Restrictions apply to the availability of these data, which were used under licence for the current study and are therefore not publicly available

However, a review of recent studies indicates that this is soon to change as more clinicians become aware of the unique advantages of nasal delivery of peptides and other therapeutics

This makes it uniquely valuable for researchers studying multi-pathway healing mechanisms and comparative recovery models

Why is the peptide a powder instead of a liquid